Ixico Regulatory News (IXI)

IXICO PLC

("IXICO" or the "Company")

Commercial agreement with PETNET Solutions Inc,

a Siemens Healthineers Company

16 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announced a commercial agreement with PETNET Solutions Inc, a Siemens Healthineers company ("PETNET") to supply diagnostic imaging agents to IXICO. This new offering is an integral part of IXICO's expansion strategy to serve its growing customer base with the latest technologies in neuroimaging.

The commercial agreement will see PETNET supplying targeted imaging agents to imaging sites used on IXICO's customers' clinical trials. Further, the agreement adds additional capability to IXICO's growing Tracer Management service offering which provides customers with use guidance, logistics and seamless integration of PET tracers in neurological clinical trials.

PETNET provides radioactive tracers for Positron Emission Tomography ("PET scans"), a widely used diagnostic approach that creates detailed three-dimensional imaging, in this use case, of the inside of the brain. Specific imaging agents may estimate β-amyloid neuritic plaque density in adult patients who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. Another tracer estimates the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease.

Bram Goorden, Chief Executive Officer of IXICO, commented:  ''IXICO continues to develop its end to end imaging service for clinical trials, and we are therefore delighted to be partnering with PETNET Solutions to provide access and supply PET tracers. This partnership is an integral part of an expanding offering and our commitment to positively impacting drug discovery and development in critical neurodegenerative illnesses such as Alzheimer's Disease.''

The announcement follows a number of commercial agreements announced throughout 2024 including significant clinical trial contract wins in Huntingdon Disease, Parkinsonian Disorder and Alzheimer's Disease, an MRI algorithm collaboration with Imeka, and a PET tracer supply agreement with Life Molecular Imaging.

Ends

Further information:

IXICO plc

Bram Goorden, Chief Executive Officer +44 (0)20 3763 7499

Grant Nash, Chief Financial Officer

This is an RNS Reach announcement, and the information contained is not considered to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

About IXICO www.IXICO.com

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.